Verde launches Deterra drug disposal pilot in Delaware
MINNEAPOLIS — Verde Technologies has announced a pilot program for its Deterra Drug Deactivation System that will see the company partner with the Delaware Prescription Action Committee (PDAC) and the Delaware Pharmacists Society to combat prescription drug abuse.
Deterra uses Verde’s Molecular Absorption Technology, which is a carbon that bonds to pharmaceutical compounds when water is added, neutralizing a drug’s active ingredient and allowing the bag to be thrown away. The product will allow Delaware residents — where since 2010 more people have died from drug overdoses than any other accidental cause — to dispose of oft-abused medication quickly without risk of them entering the water supply or landfills.
“We must take a multi-faceted approach to reducing prescription drug abuse in Delaware”" said Dr. Karyl Rattay, co-chair of the PDAC and Delaware Division of Public Health director. “Safe and secure disposal is a vital part of keeping drugs out of the hands of the wrong people and protecting our water supply. This statewide pilot is an important step in the right direction.”
Starting Aug. 18, Verde will work with pharmacists to provide 1,200 residents with qualifying prescriptions free Deterra packages that will allow them to deactivate any unused prescription medication, particularly opioids. Pharmacists will also receive training to teach residents about safe medication deactivation and disposal.
“Pharmacists play a critical role in reducing prescription drug abuse by practicing responsible dispensing of painkillers and educating patients, and now the new Deterra program provides us all with a proven tool to empower patients to safely deactivate and dispose of leftover medications at home,” said Hooshang Shanehsaz, Division of Services for Aging and Adults with Physical Disabilities pharmacy director. “It offers a convenient, cost-effective way to remove medications from the home, and ultimately prevent prescription drug abuse from starting.”
TruTag, WuXi PharmaTech successfully test edible, on-dose authentication
Mylan extends EpiPen4Schools program
PITTSBURGH — Three years after it launched its EpiPen4ASchools program, Mylan announced this week that it would continue through the 2015-2016 school year. Since the anaphylaxis awareness program began, more than 56,000 schools have enrolled in EpiPen4Schools.
"As we reflect on the first three years of the program, we are proud of the progress made to enhance anaphylaxis preparedness in schools across the country," Mylan CEO Heather Bresch said. “Up to 25% of anaphylaxis cases at school occur in those who have not been previously diagnosed with a life-threatening allergy, so we encourage eligible schools to enroll before students return this fall."
Schools who participate in the program are eligible to receive either four free EpiPen or EpiPen Jr auto-injectors, a storage unit called the EpiLocker and a training video on identifying and treating anaphylaxis that also instructs on how to properly use an EpiPen epinephrine injector. Schools can also receive an EpiPen trainer to practice, and a poster with anaphylaxis info
"This past school year, EpiPen® Auto-Injectors provided by the EpiPen4Schools program were used in two incidents,” said Connie Trent, the Health Services Facilitator for Forsyth County Schools in Cumming, Ga. "It is of utmost importance that school personnel are able to act quickly, and with the support and training resources provided through EpiPen4Schools, our staff is prepared to respond."
A recent online survey of some 6,000 participating schools found that 48.7% of anaphylactic events were treated with and EpiPen from the EpiPen4Schools program. For more information on the program, click here.